NM_000251.3:c.704_705delAA
Variant summary
Our verdict is Pathogenic. The variant received 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000251.3(MSH2):c.704_705delAA(p.Lys235ArgfsTer20) variant causes a frameshift change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000206 in 1,459,814 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000251.3 frameshift
Scores
Clinical Significance
Conservation
Publications
- Lynch syndromeInheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: G2P, ClinGen, Orphanet
- Lynch syndrome 1Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), Genomics England PanelApp, Ambry Genetics
- Muir-Torre syndromeInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Genomics England PanelApp, Orphanet, G2P
- mismatch repair cancer syndrome 1Inheritance: AR Classification: DEFINITIVE, SUPPORTIVE Submitted by: ClinGen, Orphanet
- mismatch repair cancer syndrome 2Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), G2P
- ovarian cancerInheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
- malignant pancreatic neoplasmInheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
- prostate cancerInheritance: AD Classification: MODERATE Submitted by: Ambry Genetics
- rhabdomyosarcomaInheritance: AR Classification: MODERATE Submitted by: Genomics England PanelApp
- breast cancerInheritance: AD Classification: NO_KNOWN Submitted by: Ambry Genetics
- hereditary breast carcinomaInheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD2 exomes AF: 0.00000398 AC: 1AN: 251348 AF XY: 0.00000736 show subpopulations
GnomAD4 exome AF: 0.00000206 AC: 3AN: 1459814Hom.: 0 AF XY: 0.00000138 AC XY: 1AN XY: 726344 show subpopulations
Age Distribution
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Lynch syndrome Pathogenic:3
Coding sequence variation resulting in a stop codon -
The p.Lys235fs variant in MSH2 has been reported in 3 individuals with Lynch syn drome-associated cancers (Mangold 2005, Syngal 1999) and been identified in 1/11 1640 European chromosomes by the Genome Aggregation Database (gnomAD, http://gno mad.broadinstitute.org; dbSNP rs281864944). This variant is predicted to cause a frameshift, which alters the protein?s amino acid sequence beginning at positio n 235 and leads to a premature termination codon 20 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Heterozy gous loss of function of the MSH2 gene is an established disease mechanism in in dividuals with Lynch syndrome. In addition, this variant was classified as patho genic on Sep 5, 2013 by the ClinGen-approved InSiGHT expert panel (ClinVar SCV00 0107721.2). In summary, this variant meets criteria to be classified as pathogen ic for Lynch syndrome in an autosomal dominant manner based upon presence in mul tiple affected individuals, low frequency in the general population, and the pre dicted impact on the protein. ACMG/AMP Criteria applied (Richards 2015): PVS1; P M2; PS4_Supporting. -
Variant summary: The MSH2 c.704_705delAA (p.Lys235Argfs) variant results in a premature termination codon, predicted to cause a truncated or absent MSH2 protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory (e.g. c.1030C>T/ p.Gln344X; c.1147C>T/ p.Arg383X; c.1165C>T/ p.Arg389X; c.1189C>T/ p.Gln397X). In addition, the variant of interest has been reported as pathogenic in multiple affected individuals via publications (Mangold_IJC_2005; Syngal_MLH1_JAMA_1999) and in one reputable database. One in silico tool predicts a damaging outcome for this variant. The variant of interest is absent in a large, broad control population, ExAC in 121020 control chromosomes. Taken together, this variant is classified as pathogenic. -
Hereditary cancer-predisposing syndrome Pathogenic:2
The c.704_705delAA pathogenic mutation, located in coding exon 4 of the MSH2 gene, results from a deletion of two nucleotides at nucleotide positions 704 to 705, causing a translational frameshift with a predicted alternate stop codon (p.K235Rfs*20). This mutation has been identified in one family fulfilling Amsterdam II criteria (Syngal S et al. JAMA. 1999 Jul;282:247-53), as well as in one individual of German descent fulfilling Bethesda criteria (Mangold E et al. Int. J. Cancer. 2005 Sep;116:692-702). This mutation was also detected in an individual with a family history of urinary tract cancers (Wischhusen JW et al. Cancer Epidemiol Biomarkers Prev, 2020 01;29:193-199). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
This variant deletes 2 nucleotides in exon 4 of the MSH2 gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. Splice site prediction tools suggest that this variant may not impact RNA splicing. To our knowledge, functional studies have not been performed for this variant. This variant has been reported in two suspected hereditary nonpolyposis colorectal cancer families (PMID: 10422993, 15849733) and a healthy control from a pancreatic case-control study (PMID: 29922827). This variant has been identified in 1/251348 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of MSH2 function is a known mechanism of disease. Based on the available evidence, this variant is classified as Pathogenic. -
Lynch syndrome 1 Pathogenic:1
This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation. -
not provided Pathogenic:1
This deletion of two nucleotides in MSH2 is denoted c.704_705delAA at the cDNA level and p.Lys235ArgfsX20 (K235RfsX20) at the protein level. The normal sequence, with the bases that are deleted in braces, is ACAA[AA]GACA. The deletion causes a frameshift which changes a Lysine to an Arginine at codon 235, and creates a premature stop codon at position 20 of the new reading frame. This variant is predicted to cause loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. MSH2 c.704_705delAA has been identified in association with colon cancer (Syngal 1999, Mangold 2005). We consider this variant to be pathogenic. -
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
This sequence change creates a premature translational stop signal (p.Lys235Argfs*20) in the MSH2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MSH2 are known to be pathogenic (PMID: 15849733, 24362816). This variant is present in population databases (rs281864944, gnomAD 0.0009%). This premature translational stop signal has been observed in individual(s) with Lynch syndrome (PMID: 10422993, 15849733). ClinVar contains an entry for this variant (Variation ID: 91182). For these reasons, this variant has been classified as Pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at